Henry Ford Hospital Medical Journal


The management of disseminated prostatic carcinoma with hormonal and chemotherapeutic agents is discussed. Hormonal manipulation consists of ablative as well as additive modalities. A new agent, Adriamycin, has shown some effectiveness In selected cases. Significant difficulties are encountered in assessing the objective state of remission of patients undergoing therapy. Further advances through co-operative, randomized clinical trials must be sought. The development of additional chemotherapeutic agents will hopefully expand our horizons.



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.